OrigiMed Company

OrigiMed is a medical science and technology transforming company which focuses on developing new technologies and clinical applications for all types of cancer patients. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation, they identify cancer specific molecular markers and genomic features to guide targeted or immuno-therapy, ultimately aiming to fortify the evolution of cancer precision medicine in China.

Founded Date: 42370
Last Funding Type: Series B
Headquarters: China
Investors Number: 5
Technology: diagnostics
Employee Number: 251-500
Industry: Health Care, Health Diagnostics
Estimated Revenue: Less than $1M
Last Funding Date: 2018-12-20
Funding Status: Early Stage Venture
Total Funding: $39M